A Study of ASP1002 in Adults for Treatment of Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

March 13, 2023

Primary Completion Date

April 30, 2028

Study Completion Date

May 31, 2028

Conditions
Advanced Solid Tumors
Interventions
DRUG

ASP1002

intravenous (IV) infusion

Trial Locations (15)

10029

RECRUITING

Icahn School of Medicine at Mount Sinai, New York

21632

RECRUITING

Swedish Cancer Institute, Edmonds

22031

RECRUITING

NEXT Oncology Virginia, Fairfax

29605

WITHDRAWN

Prisma Health-Upstate Cancer Institute, Greenville

32610

RECRUITING

University of Florida, Gainesville

37203

COMPLETED

SCRI Oncology Partners, Nashville

40202

RECRUITING

Norton Cancer Institute, Louisville

44106

RECRUITING

University Hospitals of Cleveland, Cleveland

48202

RECRUITING

Henry Ford Hospital, Detroit

52242

RECRUITING

University of Iowa Hospitals, Iowa City

55101

RECRUITING

HealthPartners Cancer Research Center, Saint Paul

75235

COMPLETED

University of Texas Southwestern, Dallas

75251

RECRUITING

Mary Crowley Cancer Research Center, Dallas

06520

RECRUITING

Yale University Cancer Center, New Haven

06062

RECRUITING

Hartford HealthCare Cancer Institute at The Hospital of Central Connecticut, Plainville

All Listed Sponsors
lead

Astellas Pharma Global Development, Inc.

INDUSTRY

NCT05719558 - A Study of ASP1002 in Adults for Treatment of Solid Tumors | Biotech Hunter | Biotech Hunter